
Bearish
3
Neutral
7
Bullish
4
Bearish
35
Neutral
7
Bullish
4
Bearish
32
Neutral
0
Bullish
0
30.27
▼ 0.20%
64.50
▼ 1.36%
28.26
▲ 0.18%
107.00
▼ 1.40%
67.88
▼ 0.57%
28.99
▲ 0.31%
109.32
▲ 4.79%
56.81
▼ 0.30%
45.12
▼ 1.01%
23.32
▼ 0.13%
14.94
▲ 0.20%
97.74
▼ 0.62%
239.69
▲ 0.54%
56.25
▼ 0.62%
237.07
▲ 0.45%
46.00
▼ 2.02%
238.12
▲ 3.50%
61.89
▼ 0.15%
21.42
▼ 0.33%
38.89
▲ 0.57%
67.31
▲ 1.20%
145.96
▼ 0.65%
186.80
▲ 0.00%
33.90
▼ 1.54%
44.60
▼ 0.29%
83.90
▲ 0.00%
35.36
▼ 0.42%
141.32
▼ 0.78%
56.00
▼ 0.90%
57.95
▼ 0.94%
42.00
▼ 0.92%
40
0.23%
—
—
Low Risk
0.14
—
39.4
47.83
0.903
—
Bearish
36.21
43.05
44.14
Allocation
The current market price of Motilal Oswal S&P BSE Healthcare ETF is ₹42.00. ETF prices fluctuate during market hours based on demand, supply, and movements in the underlying index or assets.
Motilal Oswal S&P BSE Healthcare ETF by Motilal Oswal Asset Management Company Limited targets returns matching BSE Healthcare TRI, pursuing a sector-specific ETF objective to replicate healthcare returns before expenses. The fund passively tracks the BSE Healthcare Total Return Index through a sector-specific replication approach, aiming index correspondence while acknowledging the objective's caveat that returns remain subject to tracking error. Portfolio concentrates in Pharmaceuticals & Biotechnology 75.6%, led by Sun Pharmaceutical Industries at 13.2%; top three holdings total 25.1%, Healthcare Services 23.7% and Equipment 0.5% showing concentration risk to investors. Performance exhibits a modest 1Y decline (1Y: -0.5%) contrasted with a robust three-year compound annual growth rate (3Y: +25.0%), notably reflecting concentrated healthcare exposure and secular strength over recent years. As of Jan 2026 fund's AUM is ₹40.2 Cr, monthly average ₹39.5 Cr, expense ratio 0.2%; managed by Mr. Swapnil Mayekar (Jul 2022, 20y) and Dishant Mehta (Oct 2024, 14y).
Motilal Oswal S&P BSE Healthcare ETF is designed to track BSE Healthcare Total Return Index, allowing investors to gain exposure to its underlying securities through a single investment.
The expense ratio of Motilal Oswal S&P BSE Healthcare ETF is 0.23%. This represents the annual fee charged by the fund house for managing the ETF and is deducted from the fund’s assets.
The Assets Under Management (AUM) of Motilal Oswal S&P BSE Healthcare ETF is approximately ₹40.21. AUM reflects the total market value of assets managed by the ETF and is often used as an indicator of fund size and liquidity.
Motilal Oswal S&P BSE Healthcare ETF is classified under the as per the risk-o-meter defined by the fund house risk category. The risk level depends on the volatility of the underlying index, market conditions, and asset composition of the ETF.
The tracking error of Motilal Oswal S&P BSE Healthcare ETF is depends on how closely the ETF follows its benchmark. Tracking error measures how closely the ETF’s performance matches its benchmark index over time.
Motilal Oswal S&P BSE Healthcare ETF does not currently declare dividends and may reinvest earnings into the fund. Dividend treatment depends on the ETF structure and fund house policy.
Based on available data, Motilal Oswal S&P BSE Healthcare ETF has delivered the following returns: 1-year return: 0.96%. 3-year return: 88.43%. 5-year return: 81.98%. Past performance does not guarantee future results.
Before investing in Motilal Oswal S&P BSE Healthcare ETF, investors generally consider the underlying index, expense ratio, tracking error, risk profile, liquidity, and how the ETF fits within their overall portfolio strategy.
| Company | Weightage (%) |
| Sun Pharmaceutical Industries Ltd. | 13.20% |
| Divis Laboratories Ltd. | 6.00% |
| Cipla Ltd. | 5.90% |
| Dr Reddys Laboratories Ltd. | 5.80% |
| Apollo Hospitals Enterprise Ltd. | 5.60% |
| Max Healthcare Institute Ltd. | 5.50% |
| Lupin Ltd. | 4.10% |
| Fortis Healthcare Ltd. | 3.50% |
| Torrent Pharmaceuticals Ltd. | 3.20% |
| Laurus Labs Ltd. | 2.90% |

AUM
₹ 40 Cr
Expense Ratio
0.23%
Performance
STEADY PERFORMER
Technicals
Bearish
Risk
—
Liquidity
POOR
Consistency
NEUTRAL